SEC fines JPM Morgan Chase for whistle-blowing violation charge
By Steve Gelsi
Bank agrees to pay $18M fine without admitting or denying wrongdoing for retail client confidentiality agreements between 2020 and 2023
JPMorgan Chase & Co. has agreed to pay an $18 million fine without admitting or denying charges by the U.S. Securities and Exchange Commission that it violated whistleblower protection rules with its confidentiality agreements during a three-year period.
The SEC said in a statement that JPMorgan (JPM) regularly asked retail clients and brokerage customer to sign confidentiality release agreements when receiving a credit or settlement from the bank of more than $1,000.
The agreements did not permit clients to voluntarily contact the SEC, although they did allow permitted clients to respond to SEC inquiries.
The SEC said the practice began in March of 2020 and ended in July of 2023.
"Whether it's in your employment contracts, settlement agreements or elsewhere, you simply cannot include provisions that prevent individuals from contacting the SEC with evidence of wrongdoing," Gurbir S. Grewal, director of the SEC's enforcement division, said in a statement. "But that's exactly what we allege J.P. Morgan did here."
A JPMorgan spokesperson said, "We take our regulatory obligations seriously and promptly took action to resolve this issue," in an email to MarketWatch.
The SEC said the confidentiality agreements "forced certain clients into the untenable position of choosing between receiving settlements or credits from the firm and reporting potential securities law violations to the SEC."
The SEC's whistleblower rule prohibits action that would impede an individual from communicating directly with its staff about possible securities law violations.
Also read: Morgan Stanley hit with $249 million fine for block-trading fraud
-Steve Gelsi
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
01-16-24 1115ET
Copyright (c) 2024 Dow Jones & Company, Inc.-
How Anti-Obesity Drugs Are Innovating the Healthcare Market
-
Why Immigration Has Boosted Job Gains and the Economy
-
What to Invest in During High Inflation
-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
Markets Brief: All Eyes On Inflation
-
5 Things We Learned From the Q1 Earnings Season
-
Baidu Earnings: Advertising Weakness Offset by Continued Growth In Cloud Business
-
Going Into Earnings, Is Target Stock a Buy, a Sell, or Fairly Valued?
-
Walmart Earnings: Low Prices and Strong Digital Presence Drive Market Share Gains
-
After Earnings and a Big Selloff, Is Shopify Stock a Buy, a Sell, or Fairly Valued?
-
Cisco Earnings: Positive Guidance and Splunk Inclusion Align With Our Long-Term Thesis
-
3 Warren Buffett Stocks to Buy After Berkshire Hathaway’s Just-Released 13F Filing
-
Going Into Earnings, Is Nvidia Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is Arista Stock a Buy, a Sell, or Fairly Valued?